Cargando…

Hydroxyapatite nanoparticles drive the potency of Toll-like receptor 9 agonist for amplified innate and adaptive immune response

The potency of Toll-like receptor 9 (TLR9) agonist to drive innate immune response was limited due to immune suppression or tolerance during TLR9 signaling activation in immune cells. Herein we addressed this problem by introducing hydroxyapatite nanoparticles (HANPs) to CpG ODN (CpG), a TLR9 agonis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Qin, Wang, Ruiqi, Hua, Yuchen, Wu, Hongfeng, Chen, Xuening, Xiao, You-cai, Ao, Qiang, Zhu, Xiangdong, Zhang, Xingdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tsinghua University Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308403/ https://www.ncbi.nlm.nih.gov/pubmed/35911480 http://dx.doi.org/10.1007/s12274-022-4683-x

Ejemplares similares

A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
por: Wu, Hongfeng, et al.
Publicado: (2022)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors
por: Wu, Hongfeng, et al.
Publicado: (2019)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Regulation of innate and adaptive immunity and autoimmunity by Toll-like receptor 9
por: Krieg, AM
Publicado: (2004)

Nano-Hydroxyapatite Coating Promotes Porous Calcium Phosphate Ceramic-Induced Osteogenesis Via BMP/Smad Signaling Pathway
por: Wang, Jing, et al.
Publicado: (2019)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
por: Cascini, Caterina, et al.
Publicado: (2023)

Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect
por: Zhang, Kun, et al.
Publicado: (2019)

Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles
por: Zhao, Rui, et al.
Publicado: (2022)

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN
por: Temizoz, Burcu, et al.
Publicado: (2015)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

The Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein, a toll-like receptor 4 agonist, enhances dendritic cell-based cancer vaccine potency
por: Noh, Kyung Tae, et al.
Publicado: (2012)

Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver
por: Jo, Juandy, et al.
Publicado: (2014)

Phylogeny of Toll-Like Receptor Signaling: Adapting the Innate Response
por: Roach, Jeffrey M., et al.
Publicado: (2013)

The GlyR Extracellular β8–β9 Loop – A Functional Determinant of Agonist Potency
por: Janzen, Dieter, et al.
Publicado: (2017)

Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue
por: Corogeanu, Diana, et al.
Publicado: (2023)

Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses
por: Dowling, David J., et al.
Publicado: (2017)

Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin
por: Coban, Cevayir, et al.
Publicado: (2005)

Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms
por: Berenson, Charles S., et al.
Publicado: (2015)

The Morphology of Hydroxyapatite Nanoparticles Regulates Cargo Recognition in Clathrin-Mediated Endocytosis
por: Zhu, Cheng, et al.
Publicado: (2021)

Innate immunity and Toll-like receptors
por: O'Neill, LAJ
Publicado: (2004)

Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
por: Cu, Yen, et al.
Publicado: (2013)

Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression
por: Calipari, Erin S., et al.
Publicado: (2013)

Toll-like receptor 4 agonist and antagonist lipopolysaccharides modify innate immune response in rat brain circumventricular organs
por: Vargas-Caraveo, Alejandra, et al.
Publicado: (2020)

Activation of the μ‐opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure
por: Åstrand, Anna, et al.
Publicado: (2020)

Electrochemical Deposition of Nanostructured Hydroxyapatite Coating on Titanium with Enhanced Early Stage Osteogenic Activity and Osseointegration
por: Lu, Minxun, et al.
Publicado: (2020)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Toxoplasma gondii-Induced Neutrophil Extracellular Traps Amplify the Innate and Adaptive Response
por: Miranda, Farlen J. B., et al.
Publicado: (2021)

The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency
por: Anderluzzi, Giulia, et al.
Publicado: (2022)

New drive amplifier for the RF separator
por: Bramham, P
Publicado: (1965)

Effects of Nanotopography Regulation and Silicon Doping on Angiogenic and Osteogenic Activities of Hydroxyapatite Coating on Titanium Implant
por: Fu, Xi, et al.
Publicado: (2020)

Neonatal innate immunity and Toll-like receptor
por: Yoon, Hye Sun
Publicado: (2010)

Toll-Like Receptors in Antiviral Innate Immunity
por: Lester, Sandra N., et al.
Publicado: (2014)

Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists
por: Meng, Wenjun, et al.
Publicado: (2011)

Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency
por: Guzelj, Samo, et al.
Publicado: (2022)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Toll, A New Piece in the Puzzle of Innate Immunity
por: Wright, Samuel D.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_5m535rq3u9cbcopfunkf59vo9s